Tilray Brands (NASDAQ:TLRY) Shares Down 4.1% – Here’s Why

Tilray Brands, Inc. (NASDAQ:TLRY)’s share price was down 4.1% on Monday . The stock traded as low as $4.47 and last traded at $4.48. 3,116,181 shares changed hands during mid-day trading, a decline of 28% from the average session volume of 4,307,043 shares. The stock had previously closed at $4.67.

Trending Headlines about Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: UK medical cannabis expansion: Tilray Medical launched its branded cannabis medicines directly to patients in the UK through Lyphe Clinic and Lyphe Dispensary. The arrangement could improve patient access, strengthen Tilray’s integrated cultivation-to-distribution platform and create a channel for commercial growth. Tilray Medical UK launch
• Positive Sentiment: More supportive German framework: Tilray Medical welcomed new guidance from Germany’s KBV and GKV-Spitzenverband for prescribing standardized full-spectrum cannabis extracts. Greater clarity could support physician confidence, patient access and broader adoption in one of Europe’s key medical cannabis markets. Germany medical cannabis framework
• Positive Sentiment: International and consumer-brand catalysts: Recent coverage highlights Tilray’s global expansion strategy. Its beverage business is also adding distribution and customer-engagement initiatives, including a second Montauk Brewing taproom in New York and BrewDog’s 2026 seasonal advent calendar. These developments may diversify revenue, though their near-term earnings contribution is unclear. Montauk Brewing expansion BrewDog advent calendar
• Neutral Sentiment: Tilray remains listed among Canadian cannabis stocks to watch, reflecting renewed sector interest after industry restructuring and cost reductions. However, the article does not identify a specific new catalyst for TLRY. Canadian cannabis stocks to watch
• Negative Sentiment: TLRY recently fell 4.07% and underperformed the broader market, indicating continued investor concern despite the expansion announcements. The company’s prior quarterly loss and history of negative earnings may keep pressure on the stock until international growth translates into stronger margins and cash flow. TLRY market underperformance

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tilray Brands in a research note on Friday, August 7th. Wall Street Zen cut Tilray Brands from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. TD Securities upgraded Tilray Brands to a “strong-buy” rating in a report on Friday, July 31st. Finally, TD Cowen lowered their price target on Tilray Brands from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Tilray Brands Trading Down 0.2%

The stock’s fifty day moving average price is $4.50 and its 200 day moving average price is $5.86. The company has a quick ratio of 1.37, a current ratio of 2.21 and a debt-to-equity ratio of 0.22. The stock has a market cap of $608.81 million, a PE ratio of -4.14 and a beta of 1.90.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings data on Tuesday, July 28th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.42). Tilray Brands had a negative return on equity of 7.76% and a negative net margin of 13.11%.The firm had revenue of $281.71 million during the quarter, compared to analysts’ expectations of $246.30 million. On average, sell-side analysts forecast that Tilray Brands, Inc. will post -0.4 EPS for the current year.

Insider Activity

In other Tilray Brands news, CFO Carl A. Merton acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were bought at an average cost of $4.62 per share, with a total value of $46,200.00. Following the completion of the transaction, the chief financial officer directly owned 139,753 shares of the company’s stock, valued at approximately $645,658.86. This represents a 7.71% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 15,000 shares of company stock worth $69,225 over the last 90 days. Corporate insiders own 0.84% of the company’s stock.

Institutional Trading of Tilray Brands

A number of institutional investors have recently made changes to their positions in TLRY. Tidal Investments LLC raised its holdings in shares of Tilray Brands by 15.0% during the second quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock valued at $12,006,000 after purchasing an additional 3,776,410 shares during the last quarter. Millennium Management LLC boosted its holdings in Tilray Brands by 281.0% in the third quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock worth $8,550,000 after purchasing an additional 3,645,060 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Tilray Brands in the third quarter worth approximately $5,813,000. Ausdal Financial Partners Inc. bought a new stake in Tilray Brands in the 2nd quarter worth approximately $939,000. Finally, Swiss National Bank raised its stake in Tilray Brands by 4.4% during the 3rd quarter. Swiss National Bank now owns 2,013,038 shares of the company’s stock valued at $3,483,000 after buying an additional 84,900 shares during the last quarter. Hedge funds and other institutional investors own 9.35% of the company’s stock.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.